• February 25 was the first ever CBD-containing drug approved in America.
  • It is intended for the treatment of severe forms of epilepsy such as Dravets or Lennox-Gastauts syndrome.

Because CBD-based drugs have entered the market, the agency promises to counteract cannabidiol product manufacturers that cause side effects.

On 25 June 2018, the US Food and Drug Administration approved a medicine containing marijuana, Epidiolex, for the treatment of rare forms of epilepsy. Treatment oit contains cannabidiol or CBD and does not create euphoric conditions, while reducing seizure rates in patients with Dravet or Lennox-Gastraut syndrome, as reported in clinical trials.

"In my practice, I often encounter patients with epilepsy that is highly resistant to treatment. Patients have tried existing therapies that have failed to ask CBD," says Orrin Devinsky of NYU Langone Health, senior investigator in company studies. which produces Epidiolex. "I am very pleased with my colleagues. We will now be able to prescribe cannabidiol, which has been strictly controlledstudy and was approved by the FDA to treat both children and adults.

Dravet and Lennox-Gastaut Syndrome

Dravet's and Lennox-Gastaut's syndrome are quite severe forms of epilepsy that can be fatal. While there are other drugs approved for the treatment of Lennox-Gastaut's syndrome, there has been no treatment for Dravet's syndrome. Some parents used untreated CBD oils to treat their children. In a published statement, the FDA states that "it has taken recent action against companies that distribute unapproved CBD products. We will continue to take action if we see the illegal sale of CBD containing products with unknown health effects."

"I'm really glad we have a product that will be much cleaner and whose composition I know," said AP Ellaine Wirrell, Mayo Clinic Director for Childhood Epilepsy. "In handmade products, there is often a huge difference in bottle-bottle dose, depending on where you buy it."

Heather Jackson of the Realm of Caring, a CBD charitable organization CW Hemp, said, "I don't know if my father or mother is going to reevaluate something that already works. I really don't think (FDA approval) will affect us."

Source: z. ” The New York Times , The New York Times, July 8, 2018